Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue
+1.33%
EPS
+418.2%
Free cash flow
−6.83%
Total debt
−42.2%

Quarter to June 2026, against a year earlier

72.76 0.10 +0.14%
Market cap
$11.4B
P/E
62.2×
Fwd P/E
54.2×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100

Bio-Techne Corp (TECH) Free cash flow

Alert me on Free cash flow

Bio-Techne Corp's free cash flow for fiscal 2026 was $263.2M, unchanged from fiscal 2025. Over the past ten years it has ranged from $119.5M (fiscal 2015) to $307.9M (fiscal 2021); the current reading is higher than 83% of that period. Free cash flow has risen for 3 consecutive fiscal years. Bio-Techne Corp ranks 16th of 603 Biotechnology companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2026 $263.2M 2.60%
FY2025 $256.6M 8.66%
FY2024 $236.1M 9.23%
FY2023 $216.1M (22.90%)
FY2022 $280.4M (8.93%)
FY2021 $307.9M 100.60%
FY2020 $153.5M (1.75%)
FY2019 $156.2M 4.53%
FY2018 $149.4M 16.25%
FY2017 $128.5M 1.01%

Quarterly newest first

Period Free cash flow Change
Jun 2026 $86.9M 12.07%
Mar 2026 $77.6M 1.42%
Dec 2025 $76.5M 244.21%
Sep 2025 $22.2M (76.19%)
42 more quarters

Against its own ten years

Low $119.5M High $307.9M
Ten-year median $186.2M
Current reading's percentile 83

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on TECH